Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

What Was Tested

The paper reports a study of Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.

Who Took Part

The study group was 656 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

The patients were allocated by chance, so the Amylin (Islet Amyloid Polypeptide) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Amylin (Islet Amyloid Polypeptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Amylin (Islet Amyloid Polypeptide) could be set against what happens without it.

More than one site took part, so the patients came from several places.

What Was Measured

The subject headings attached to it are Amyloid, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Incidence.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) in 656 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.